Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 30, 1996

View Archived Issues

New agents for CNS disorders claimed by HHS

Beiersdorf-Lilly claims angiotensin II blockers

New cephalosporins from LG Chemical

Dual-action compounds with antiasthma activity reported by Kowa

Medarex claims bispecific reagents for AIDS therapy

British researchers describe anticytokine antisense peptides

Company Profile: Celgene Corporation

Company Profile: Connective Therapeutics

Company Profile: MorphoSys

Company Profile: Shaman Pharmaceuticals

LJP licenses rights to drug for lupus

Further approval for breakthrough glaucoma medication

Andrx licenses chemoprotective agent to Asta

First phase II results for Innapharma's peptide antidepressant

European approval recommended for CMV retinitis Rx

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...